Please login to the form below

Not currently logged in

Video interview with Baroness Julia Neuberger

Baroness Julia Neuberger, winner of the 2010 Communiqué Award for Healthcare Communications Advocate, talks to John Clare about her key achievements and gives her view on current hot topics including NHS Reform

The Communiqué Awards, which recognise best practice in healthcare communications, took place in July this year. As she had been unable to attend to collect her prize for Healthcare Communications Advocate in person, John Clare CEO of LionsDen Communications caught up with Baroness Julia Neuberger. 

In this video interview, Baroness Neuberger talks about the key achievements in her career to date, which includes the 'Enhancing the healing environment' programme for which she was responsible during her time as chief executive of the King's Fund. 

Baroness Neuberger goes on to talk to John about what she would change if she were secretary of state for health and speaks frankly about her views on pharmaceutical companies involvement in medical education.


The full interview will be published in the December issue of Pharmaceutical Marketing magazine and includes Baroness Neuberger's views on pharmaceutical companies and their partnerships with the NHS, her opinion on clinical trial processes and her views on NHS Reform.

The interviewer
John Clare is CEO of LionsDen Communications
To comment on this article email  

10th November 2010


Featured jobs

Subscribe to our email news alerts


Add my company

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Revisiting Instagram for pharma
In pharma, Instagram usage is increasing because it offers so many benefits to engage with patients and HCPs...
The one multichannel question you must ask
There is a question every marketer should ask when designing a multichannel communications strategy...
Medius Deal Watch
Deal Watch September 2016
Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up...